EDITORIAL

Can Our Hearts Take the New Guidelines?
Eitan Frankel, MD

After getting sign-out for the Heart Failure service, I
excitedly went to meet Mr. G. Two months ago, while
on a different service, I frequently watched him bustle
through the hospital hallways with his IV pole in hand.
He smiled, spoke cordially with nurses and staff, and
took time to greet house-staff not directly involved with
his care. Thus, you can imagine my surprise when I
entered his room and encountered a forlorn face with a
few days of stubble complaining about cold eggs and
toast. He hadn’t been on a walk in days.
Unfortunately, the scene I am describing is likely familiar
to anyone involved with inpatient, heart failure care. Mr.
G is a 67 year-old-male with ischemic cardiomyopathy
(left ventricular ejection fraction 10-15%) on outpatient
milrinone who was admitted for expedited heart
transplant evaluation in the setting of worsening
symptoms and hemodynamics. His milrinone was
increased to the maximum dose and a Swan Ganz
catheter was placed. In early September 2018, he was
listed as status 1A, the highest level prior to transplant.
For the next month, Mr. G cheerfully greeted the resident
at 7am, persuaded nurses to slip him extra chocolate,
and set new records on his daily walks.
Then overnight, on October 18th 2018, the new transplant
listing criteria went into effect and everything changed.
Allocation of organ transplantation in the United States
is managed by the United Network for Organ Sharing
(UNOS) and is dependent on an intricate system. Due to
the relative scarcity, there is no easy way to justly and
effectively allocate hearts. Over the past few years,
there had been a growing consensus that the old listing
system had significant problems: there were too many
status 1A patients, there was inadequate organ allocation
to certain high risk candidates, allocation rules were not
aligned with prognosis, and there were unintended
geographic disparities.1 Thus, in October, a new set of
guidelines went into effect that changed the criteria for
urgency status (Table 1) and increased the geographical
distance for organ procurement to 500 miles.2 According
to the new guidelines, only three categories of patients
are considered Status 1: those on VA ECMO (who can be
listed as Status 1 for 7 days), those who are
non-dischargeable with biventricular devices, and those
who have mechanical circulatory support devices and
life-threatening arrhythmias. 2 These changes to the
criteria for medical urgency in orthotopic heart
transplants were not unexpected, but there remain
unsolved system-wide and patient-centered questions
that the cardiology community needs to address.
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One question is what will happen to the metric of
one-year survival after transplant? While one-year
survival has traditionally been the gold standard for
evaluating transplant programs, historical data suggests
that if programs elect to transplant the highest risk
patients (i.e. ECMO patients), outcomes will worsen.
Since the 1980s, the International Society for Heart and
Lung Transplantation (ISHLT) has compiled a registry of
141,268 heart transplants and published an annual report
with statistics and outcome data. 3 As mechanical
circulatory support (MCS) has become safer and more
efficacious, an increasing number of transplants are
being bridged by MCS (26.0% from 2004 to 2008 vs.
43.0% from 2009-2014). 3 While patients with left
ventricular assist devices, biventricular assist devices,
and no mechanical support (plus or minus inotropes) do
comparably well after transplant, extracorporeal
membrane oxygenation (ECMO) patients continue to
lag in their one-year survival rates (80-85% vs 60%,
p<.05).4 A separate retrospective cohort study looking at
post-heart transplant mortality among 157
ECMO-supported adults between 2000 and 2015
demonstrated similar results. The overall one-year
survival rate was 57.8%, and it was significantly worse
among patients with renal insufficiency (defined as GFR
<45 ml/min/1.73 m2 or dialysis dependent), mechanical
ventilation, or both of these comorbidities (52.3% vs
55.3% vs 12.5%).4 It is important to note that there are
significant limitations to each of these studies; both
studies were retrospective and did not evaluate center
expertise. While it is possible transplant outcomes
among ECMO patients may improve with increasing
usage and familiarity, it is unlikely that 1-year survival will
reach the 90% one-year survival benchmark to which
programs are currently held accountable. Given this
existing historical data, current transplant programs will
have to make a difficult decision: whether to take
advantage of increased donor availability for Status 1A
patients and accept the risk of transplanting high-risk
patients, or whether to defer operating on these patients
in order to protect outcome statistics.
While the validity of one-year survival as a metric of
transplant program success is only one of many
system-wide issues related to the new guidelines, this
conversation would be incomplete without returning to
the case of Mr. G and focusing on the patient-centered
effects. Even though Mr. G did not miraculously improve
or titrate off inotropes, overnight his listing status
changed from 1A to 3. At a statistical level, the outcomes
of old Status 1A and new Status 3 can be compared.

Table 1: PFTs from September 2016
Criteria Requirements in Adult Heart Allocation Policy
Old Guidelines
Status

Criteria

New Guidelines
Status
1

1A

1B
2

7

"Transplant candidate must be admitted to listing
transplant center hospital and have at least one of the
following devices or therapies in place:
1) Mechanical circulatory support for acute hemodynamic
decompensation (LVAD <30 days,
TAH, IABP, ECMO)
2) MCS with device complications
3) Continuous mechanical ventilation
4) Continuous infusion of a single high-dose intravenous
inotrope or multiple intravenous inotropes, in addition to
continuous hemodynamic monitoring of left ventricular
filling pressures"

"Transplant candidate listed must have at least one of the
following devices or therapies in place:
1) Left and/or right ventricular assist device implanted
2) Continuous infusion of intravenous inotropes"

2

3

This data will take a few years to collect, but hopefully
our patients will do just as well as before. But much
more difficult to measure will be the emotional and
psychological effects of the shifting guidelines on
current transplant candidates.
Mr. G was devastated when he heard his status had been
downgraded to Status 3. After remaining upbeat and
hopeful for months, while feeling that he was slowly
approaching the end of the tunnel, he suddenly had no
idea if or when he might receive a transplant. The
unpaid bills at home and his familial responsibilities
started taking a toll on his mood, and the once hospital
marathoner grew increasingly despondent and
frustrated; he frequently discussed leaving the hospital
without a new heart. And while he understood that that
there were valid reasons behind the guideline changes,
he still felt betrayed by the system and the fact that he
wasn’t grandfathered in.

"1) VA ECMO
2) Non-dischargeable, surgically implanted, non-endovascular
biventricular support device
3) MCSD with life-threatening ventricular arrhythmias"
"1) Non-dischargeable, surgically implanted, non-endovascular LVAD
2) IABP
3) Vtach/Vfib
4) MCSD with device malfunction
5) TAH, BiVAD, RVAD, or VAD
6) Percutaneous endovascular MCSD "
"1) Dischargeable LVAD (<30 days)
2) Multiple inotropes or single high-dose inotrope with continuous
hemodynamic monitoring
3) VA ECMO after 7 days; percutaneous endovascular circulatory
support device or IABP after 14 days
4) Non-dischargeable, surgically implanted, non-endovascular LVAD
after 14 days
5) MCSD with device infection. hemolysis, pump thrombosis, right heart
failure, mucosal bleeding, aortic insufficiency"

4

"1) Dischargeable LVAD
2) Inotrope without hemodynamic monitoring
3) Re-transplant
4) Congenital heart disease, intractable angina, HCM, restrictive cardiomyopathy, amyloidosis"

5

On the waitlist for at least one other organ at the same hospital

6

All remaining active candidates

A transplant candidate who does not meet the criteria for
Status 1A or 1B
A transplant candidate who is considered temporarily
unsuitable to receive a heart transplant

Criteria
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And I don’t blame him one bit.
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